The Food and Drug Administration on May 3 approved the first U.S. vaccine for respiratory syncytial virus, Arexvy by GlaxoSmithKline Biologicals, for use in individuals aged 60 and older.  

“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Headline
The Trump administration yesterday released executive orders on reducing anti-competitive regulatory barriers and repealing certain regulations deemed unlawful…
Headline
The Office of Management and Budget April 9 released a notice seeking public input on rules to potentially be rescinded, requesting detailed reasons…
Perspective
Congress returns to Washington, D.C., next week following the summer recess, and lawmakers can expect a busy fall as they face a full plate of issues that need…
Perspective
While Congress passed legislation last month to fund the federal government through September, it’s looking like there will be very few other pieces of…
Headline
The Centers for Medicare & Medicaid Services Feb. 8 released a proposed rule intended to strengthen oversight of organizations that accredit health care…